REPORT ID 6964

EMEA (Europe, Middle East and Africa) Anti-Obesity Drugs Market Report 2017

Publish Date
1-Nov-17
Pages
116
Format
Electronic (PDF)

In this report, the EMEA Anti-Obesity Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Anti-Obesity Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Anti-Obesity Drugs market competition by top manufacturers/players, with Anti-Obesity Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer
    Merck
    F.Hoffmann-La Roche
    GlaxoSmithKline
    AstraZeneca
    Boehringer Ingelheim
    Novo Nordisk
    Eisai
    Norgine
    Arena Pharmaceuticals
    Orexigen Therapeutics
    Vivus
    Alizyme
    Rhythm Pharmaceuticals
    Shionogi
    Zafgan

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Prescription Drugs
    OTC drugs

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Anti-Obesity Drugs for each application, including
    6-18 Callant
    18-30 Adult
    30-60Middle-Aged
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Anti-Obesity Drugs Market Report 2017
1 Anti-Obesity Drugs Overview
    1.1 Product Overview and Scope of Anti-Obesity Drugs
    1.2 Classification of Anti-Obesity Drugs
        1.2.1 EMEA Anti-Obesity Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Anti-Obesity Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Prescription Drugs
        1.2.4 OTC drugs
    1.3 EMEA Anti-Obesity Drugs Market by Application/End Users
        1.3.1 EMEA Anti-Obesity Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 6-18 Callant
        1.3.3 18-30 Adult
        1.3.4 30-60Middle-Aged
        1.3.5 Others
    1.4 EMEA Anti-Obesity Drugs Market by Region
        1.4.1 EMEA Anti-Obesity Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Anti-Obesity Drugs (2012-2022)
        1.5.1 EMEA Anti-Obesity Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Anti-Obesity Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Anti-Obesity Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Anti-Obesity Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Anti-Obesity Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Anti-Obesity Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Anti-Obesity Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Anti-Obesity Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Anti-Obesity Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Anti-Obesity Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Anti-Obesity Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Anti-Obesity Drugs (Volume) by Application
    2.4 EMEA Anti-Obesity Drugs (Volume and Value) by Region
        2.4.1 EMEA Anti-Obesity Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Anti-Obesity Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Anti-Obesity Drugs Sales Price by Region (2012-2017)

3 Europe Anti-Obesity Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Anti-Obesity Drugs Sales and Value (2012-2017)
        3.1.1 Europe Anti-Obesity Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Anti-Obesity Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Anti-Obesity Drugs Sales and Market Share by Type
    3.3 Europe Anti-Obesity Drugs Sales and Market Share by Application
    3.4 Europe Anti-Obesity Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Anti-Obesity Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Anti-Obesity Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Anti-Obesity Drugs Sales and Growth Rate (2012-2017)

4 Middle East Anti-Obesity Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Anti-Obesity Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Anti-Obesity Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Anti-Obesity Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Anti-Obesity Drugs Sales and Market Share by Type
    4.3 Middle East Anti-Obesity Drugs Sales and Market Share by Application
    4.4 Middle East Anti-Obesity Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Anti-Obesity Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Anti-Obesity Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Anti-Obesity Drugs Sales and Growth Rate (2012-2017)

5 Africa Anti-Obesity Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Anti-Obesity Drugs Sales and Value (2012-2017)
        5.1.1 Africa Anti-Obesity Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Anti-Obesity Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Anti-Obesity Drugs Sales and Market Share by Type
    5.3 Africa Anti-Obesity Drugs Sales and Market Share by Application
    5.4 Africa Anti-Obesity Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Anti-Obesity Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Anti-Obesity Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Anti-Obesity Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Anti-Obesity Drugs Sales and Growth Rate (2012-2017)

6 EMEA Anti-Obesity Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Pfizer
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Pfizer Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Merck
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Merck Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 F.Hoffmann-La Roche
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 F.Hoffmann-La Roche Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 GlaxoSmithKline
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 GlaxoSmithKline Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 AstraZeneca
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 AstraZeneca Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Boehringer Ingelheim
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Boehringer Ingelheim Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Novo Nordisk
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Novo Nordisk Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Eisai
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Eisai Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Norgine
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Norgine Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Arena Pharmaceuticals
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Anti-Obesity Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Arena Pharmaceuticals Anti-Obesity Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Orexigen Therapeutics
    6.12 Vivus
    6.13 Alizyme
    6.14 Rhythm Pharmaceuticals
    6.15 Shionogi
    6.16 Zafgan

7 Anti-Obesity Drugs Manufacturing Cost Analysis
    7.1 Anti-Obesity Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Anti-Obesity Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Anti-Obesity Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Anti-Obesity Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Anti-Obesity Drugs Market Forecast (2017-2022)
    11.1 EMEA Anti-Obesity Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Anti-Obesity Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Anti-Obesity Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Anti-Obesity Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Anti-Obesity Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Anti-Obesity Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Anti-Obesity Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Anti-Obesity Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Anti-Obesity Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Anti-Obesity Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer